IPP Bureau
Roche to acquire 89bio in $3.5B deal
By IPP Bureau - September 20, 2025
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12
By IPP Bureau - September 19, 2025
Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration
By IPP Bureau - September 19, 2025
This predictive technology empowers people with diabetes to take preventive action before complications arise
Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025
By IPP Bureau - September 19, 2025
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials
By IPP Bureau - September 19, 2025
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar
By IPP Bureau - September 19, 2025
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Sai Life Sciences opens dedicated facility for veterinary APIs in Bidar
By IPP Bureau - September 19, 2025
Merck opens €150 million manufacturing facility in Ireland
By IPP Bureau - September 19, 2025
Merck opens first climate-neutral manufacturing facility in Ireland
FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations
By IPP Bureau - September 19, 2025
The inspection concluded with zero form 483 observations
AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
By IPP Bureau - September 18, 2025
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Novo Nordisk’s Wegovy delivered 16.6% weight loss
By IPP Bureau - September 18, 2025
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Bayer inaugurates new phytomedicines lab facility
By IPP Bureau - September 18, 2025
The lab will facilitate the development of herbal and natural-based solutions
Bayer launches biotech innovation platform in China
By IPP Bureau - September 17, 2025
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma and FABRX announce strategic partnership
By IPP Bureau - September 17, 2025
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
GSK to invest $30 billion in R&D, manufacturing in US over next 5 years
By IPP Bureau - September 17, 2025
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
